Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Clarke

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Research Square|July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 StudyEziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
International Journal of Radiation Oncology, Biology, Physics|January 19, 2023
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey L Liveringhouse, Kujtim Latifi, Amalin G Asous, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Research Square|July 3, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 StudyEziafa Oduah, Jhanelle Gray, Thomas Stinchcombe, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
International Journal of Radiation Oncology, Biology, Physics|January 19, 2023
Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey L Liveringhouse, Kujtim Latifi, Amalin G Asous, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Pageof 2